Xerion Limited
Xerion is an Australian based specialty pharmaceutical company whose focus is to build a US prescription drug pipeline of 5 new products using AMYCOT® for key dermatological indications. Xerion is currently conducting a $6 million Series A funding round and an IPO is planned in the next 12 months providing early investors a viable exit strategy.
First Name
Last Name
Company
Email
Phone (including country code)
Country
Intentions Investor Service Provider Industry Participant
Comments
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.